Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialKohei Shitara, Jaffer A. Ajani, Florian Lordick et al.|The Lancet|2023Cited by 701
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialManish A. Shah, Rui‐Hua Xu, Kohei Shitara et al.|Nature Medicine|2023Cited by 541
Paclitaxel in the treatment of patients with angiosarcoma of the scalp or faceFarid Fata, Ephraim S. Casper, Eileen M. O’Reilly et al.|Cancer|1999Cited by 388
Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trialCharles S. Fuchs, Francesco Di Costanzo, Michel Ducreux et al.|The Lancet Oncology|2019Cited by 282
RETRACTED: Circulating tumor DNA status to direct adjuvant immunotherapy for mismatch repair deficient tumorsYelena Y. Janjigian, Luis A. Díaz, Melissa Lumish et al.|Research Square|2025Cited by 0